What is the 13F Pro Quality Score for IOVA?

13F Pro ranks IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IOVA's current score at https://13fpro.ai/company/IOVA (free sign-up required for the full ranking).

Which hedge funds own the most IOVA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IOVA include BlackRock,, MHR FUND MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/IOVA as soon as new 13F filings post.

Where does 13F Pro source IOVA data?

All IOVANCE BIOTHERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. IOVANCE BIOTHERAPEUTICS, INC. files with the SEC under CIK 1425205. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IOVA in?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IOVA research updated on 13F Pro?

IOVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IOVANCE BIOTHERAPEUTICS, INC.(IOVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1425205 IOVA stock profile & AI dashboard →

13F Pro Quality Score

36.8/100

Rank #2,253 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

8.1/100

Balance Sheet

7.3/100

Earnings Quality

13.4/100

Free Cash Flow

6.8/100

Institutional Flow

71.5/100

Revenue Scale

30.8/100

Dilution Risk

7.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IOVA Scores 37/100

exact factor attribution · 2026-09-11

IOVA's composite is driven by revenue growth and earnings growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Earnings growth

+1.5 pts

80th pct

Institutional flow

+1.1 pts

72th pct

Shareholder dilution

-2.1 pts

8th pct

Scale

-2.9 pts

31th pct

Earnings quality

-3.7 pts

13th pct

Capital efficiency

-4.3 pts

7th pct

Profitability

-6.3 pts

8th pct

Free cash flow

-6.5 pts

7th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IOVA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IOVANCE BIOTHERAPEUTICS, INC. (IOVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IOVA at 36.8/100 on a 32-signal composite quality model, placing it at rank #2,253 of 2,962 stocks — the bottom half of the AI-ranked universe. IOVA scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (6.8) and balance sheet strength (7.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IOVANCE BIOTHERAPEUTICS, INC. reports quarterly revenue of $99.3M, net income of $-47.3M, free cash flow of $-66.3M. Top institutional holders of IOVA by reported 13-F value include BlackRock, MHR FUND MANAGEMENT, STATE STREET, based on the most recent SEC filings. IOVA trades on the Nasdaq exchange and files with the SEC under CIK 1425205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IOVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IOVANCE BIOTHERAPEUTICS, INC. directly from SEC EDGAR. IOVANCE BIOTHERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 29 and 42 since 2024, currently 36.8 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about IOVANCE BIOTHERAPEUTICS, INC.

Quirks, history, and lore behind IOVA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · focused on cell therapy for cancer patients.
2
The Numbers
Its first commercial product only recently launched, meaning revenue is still ramping from near zero — yet the company carries a market cap in the low billions on the promise of its pipeline.
3
The History
Founded in the 2010s, the company spent years in clinical trials before winning FDA approval for a treatment targeting a notoriously hard-to-treat skin cancer.
4
The Secret
Its core technology uses a patient's own tumor-infiltrating lymphocytes — immune cells extracted, multiplied in a lab, and infused back — essentially turning the body into its own cancer-fighting factory.
5
The Lore
Its first approved therapy, Amtagvi, made history in early 2024 as the first TIL cell therapy ever greenlit by the FDA — a milestone the oncology world had been watching for decades.
6
The Giveaway
Ticker IOVA, pioneer of TIL therapy, and the company whose name literally starts with the Latin root for "violet" — as in melanoma, the dark-pigmented cancer it set out to conquer.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$99.3M

Net Income

Q2 2026

$-47.3M

Free Cash Flow

Q2 2026

$-66.3M

ROIC

Q2 2026

-28.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+60.6% YoY

$263.5MFY 2025

FY22 —FY23 $1.2MFY24 $164.1MFY25 $263.5M

Net Income

-5.1% YoY

$-391.0MFY 2025

FY22 $-395.9MFY23 $-444.0MFY24 $-372.2MFY25 $-391.0M

Operating Income

-2.0% YoY

$-403.4MFY 2025

FY22 $-398.9MFY23 $-460.6MFY24 $-395.3MFY25 $-403.4M

EPS (Diluted)

+14.8% YoY

$-1.09FY 2025

FY22 $-2.49FY23 $-1.89FY24 $-1.28FY25 $-1.09

Total Assets

+0.3% YoY

$913.2MFY 2025

FY22 $664.0MFY23 $780.4MFY24 $910.4MFY25 $913.2M

Op. Cash Flow

+14.3% YoY

$-302.4MFY 2025

FY22 $-292.8MFY23 $-361.8MFY24 $-353.0MFY25 $-302.4M

Free Cash Flow

+7.6% YoY

$-336.2MFY 2025

FY22 $-313.2MFY23 $-384.1MFY24 $-364.0MFY25 $-336.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$263.5M +60.6%	$164.1M +13699.0%	$1.2M	—	—	—
Net Income	$-391.0M -5.1%	$-372.2M +16.2%	$-444.0M -12.2%	$-395.9M -15.7%	$-342.3M -31.8%	$-259.6M
Operating Income	$-403.4M -2.0%	$-395.3M +14.2%	$-460.6M -15.5%	$-398.9M -16.4%	$-342.7M -30.8%	$-261.9M
EPS (Diluted)	$-1.09 +14.8%	$-1.28 +32.3%	$-1.89 +24.1%	$-2.49 -11.7%	$-2.23 -18.6%	$-1.88
Total Assets	$913.2M +0.3%	$910.4M +16.7%	$780.4M +17.5%	$664.0M -14.6%	$777.3M +1.2%	$768.5M
Operating Cash Flow	$-302.4M +14.3%	$-353.0M +2.4%	$-361.8M -23.6%	$-292.8M -28.4%	$-227.9M -11.1%	$-205.1M
Free Cash Flow	$-336.2M +7.6%	$-364.0M +5.2%	$-384.1M -22.6%	$-313.2M -18.0%	$-265.5M -5.4%	$-251.9M

Get alerted when IOVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IOVANCE BIOTHERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IOVA

BlackRock, Inc.
$153.7M36,957,681 sh
MHR FUND MANAGEMENT LLC
$120.5M28,967,103 sh
STATE STREET CORP
$101.8M24,478,268 sh
TWO SIGMA INVESTMENTS, LP
$79.1M19,010,697 sh
VANGUARD CAPITAL MANAGEMENT LLC
$75.7M18,204,248 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$59.9M14,388,999 sh
GEODE CAPITAL MANAGEMENT, LLC
$43.0M10,324,826 sh
MILLENNIUM MANAGEMENT LLC
$35.5M8,525,919 sh
DIMENSIONAL FUND ADVISORS LP
$26.9M6,460,449 sh
Palo Alto Investors LP
$22.0M5,296,209 sh

Fund	Value	Shares
BlackRock, Inc.	$153.7M	36,957,681
MHR FUND MANAGEMENT LLC	$120.5M	28,967,103
STATE STREET CORP	$101.8M	24,478,268
TWO SIGMA INVESTMENTS, LP	$79.1M	19,010,697
VANGUARD CAPITAL MANAGEMENT LLC	$75.7M	18,204,248
VANGUARD PORTFOLIO MANAGEMENT LLC	$59.9M	14,388,999
GEODE CAPITAL MANAGEMENT, LLC	$43.0M	10,324,826
MILLENNIUM MANAGEMENT LLC	$35.5M	8,525,919
DIMENSIONAL FUND ADVISORS LP	$26.9M	6,460,449
Palo Alto Investors LP	$22.0M	5,296,209

Companies Similar to IOVA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

KURA

Kura Oncology, Inc.

AI score

Similar quality profile · 14 shared holders

Rhenman & Partners Asset Management AB JUPITER ASSET MANAGEMENT LTD SECTOR GAMMA AS

VIR

Vir Biotechnology, Inc.

AI score

Similar quality profile · 12 shared holders

Susquehanna Portfolio Strategies, LLC Raiffeisen Bank International AG Soleus Capital Management, L.P.

ARDX

ARDELYX, INC.

AI score

Similar quality profile · 14 shared holders

SECTOR GAMMA AS Hennion & Walsh Asset Management, Inc.Raiffeisen Bank International AG

RARE

Ultragenyx Pharmaceutical Inc.

AI score

Similar quality profile · 14 shared holders

Palo Alto Investors LP B Group, Inc.VOLORIDGE INVESTMENT MANAGEMENT, LLC

SNDX

Syndax Pharmaceuticals Inc

AI score

Similar quality profile · 14 shared holders

Palo Alto Investors LP JUPITER ASSET MANAGEMENT LTD Rhenman & Partners Asset Management AB

IBRX

ImmunityBio, Inc.

AI score

Similar quality profile · 14 shared holders

Hennion & Walsh Asset Management, Inc.VOLORIDGE INVESTMENT MANAGEMENT, LLC Virtus Investment Advisers, LLC

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

AI score

Similar quality profile · 8 shared holders

Rhenman & Partners Asset Management AB Orion Investment Co Virtus Investment Advisers, LLC

NVCR

NovoCure Ltd

AI score

Similar quality profile · 10 shared holders

Palo Alto Investors LP C WorldWide Group Holding A/S Susquehanna Portfolio Strategies, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IOVA on your watchlist

Track score changes the day IOVANCE BIOTHERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IOVA a good stock to buy?

13F Pro's AI-powered analysis of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IOVA are available on the IOVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IOVA is classified as a mid company.

Which hedge funds own IOVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IOVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IOVANCE BIOTHERAPEUTICS, INC.'s investment landscape.